Fish oil formula could tame inflammation in rare lung disease
NCT ID NCT07697235
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study tests whether a specially formulated omega-3 supplement, with a high ratio of EPA to DHA, can reduce inflammation and improve blood vessel function in people with pulmonary arterial hypertension (PAH). Participants take four capsules daily for 12 weeks alongside their usual PAH medications. The goal is to see if this nutritional approach can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Omega-3 fatty acids (EPA and DHA in a 6:1 ratio)
- What this could lead to
- If successful, this could point toward a simple nutritional supplement to help manage inflammation and blood vessel health in people with PAH.
- What could go wrong
- This is a small, early-stage study with only 22 participants, so results may not apply to everyone. The supplement is tested alongside standard care, not as a replacement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.